VIV:TSX.V

Avivagen Inc.

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.
VIV:TSX.V

Expert Comments:

Technical analyst Clive Maund believes this stock could gain traction soon.
read more >
The developer received an initial order from Taiwan for the product.
read more >
Demand for the Canadian company's product is growing in the Asia-Pacific region.
read more >
The country represents a significant market for feed consumption.
read more >
The new partner has expertise in online marketing and e-commerce.
read more >

Clive Maund, CliveMaund.com

(5/11/19)
"This looks like an excellent point to buy back Avivagen Inc. . .the price is believed to be completing an intermediate base after correcting back to support. Volume indications are very favorable. . .rated an Immediate Strong Buy."

Alex Koyfman, Penny Stock Millionaire

(2/22/19)
"Avivagen Inc. announced earlier this week that it has signed a partnership with CSA Animal Nutrition providing for the sales and distribution of OxC-beta livestock by CSA in the U.S. . .under the terms of the agreement, CSA will coordinate commercial-scale validation research with potential customers and fulfill a sales and distribution role with OxC-beta for poultry, swine and dairy cattle."

Clive Maund, CliveMaund.com

(10/28/18)
"Avivagen Inc.'s stock has continued to strengthen, and most importantly it has been impervious to the crashing stock market, which doesn't seem to have affected it at all. The purpose of this update is to draw your attention to this and also to the fact that it appears to be getting ready to break out to the upside, which could happen at any time now. . .we therefore stay long, and it is rated an immediate Strong Buy here."

Alex Koyfman, Penny Stock Millionaire

(10/26/18)
"Avivagen Inc.'s products are tested and have shown to have substantial benefits over existing methodology in an industry that is universally crucial. . .the company's recent progress in signing distribution deals in the Far East illustrates both the demand for the technology and future prospect in markets around the world."

Experts Following This Company

Alex Koyfman, Newsletter Writer – First Call
Clive Maund – CliveMaund.com
headshot of Steve Palmer
Steve Palmer, President and Chief Investment Officer – AlphaNorth Asset Management

The information provided above is from analysts, newsletters, the company and other contributors.

Avivagen Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Effective natural substitute for antibiotics in animal feed
 
Six families of patents extending beyond 2035
 
Antibiotic ban in animal feed being led by Governments
catalyst Calendar
Q1
2019
Nutraceutical deal/JV
Q3
2019
GRAS approval for livestock in the USA
Q4
2019
Chinese approval for livestock
Avivagen Inc. Content